Verition Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Verition Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47M	Buy	+6,000	New	+$1.3M	0.01%	1259
2026 Q1	–	Sell	-3,409	Closed	-$623K	–	2338
2025 Q4	$623K	Buy	3,409 +1,420	+71%	+$198K	﹤0.01%	2494
2025 Q3	$242K	Buy	+1,989	New	+$224K	﹤0.01%	3398
2025 Q2	–	Sell	-28,998	Closed	-$3.38M	–	3632
2025 Q1	$3.38M	Buy	28,998 +23,650	+442%	+$2.69M	0.02%	1175
2024 Q4	$452K	Buy	+5,348	New	+$492K	﹤0.01%	2543
2023 Q2	–	Sell	-9,316	Closed	-$575K	–	2206
2023 Q1	$575K	Buy	+9,316	New	+$612K	0.01%	1162
2022 Q4	–	Sell	-10,943	Closed	-$488K	–	2145
2022 Q3	$488K	Buy	+10,943	New	+$547K	0.01%	1904
2020 Q2	–	Sell	-33,200	Closed	-$1.95M	–	1052
2020 Q1	$1.95M	Buy	+33,200	New	+$2.71M	0.08%	172

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verition Fund Management's AXSM Position: Q2 2026 in Review

Verition Fund Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 6,000 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in AXSM as recently as Q4 2025.

Verition Fund Management first reported a position in AXSM in Q1 2020 and has held it in 8 quarters since. The position peaked at $3.38M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Verition Fund Management held 6,000 shares of Axsome Therapeutics worth $1.47M as of Q2 2026.
Axsome Therapeutics was a new Verition Fund Management position in Q2 2026.
Axsome Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1259 holding.
Verition Fund Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 8 quarters since.
Verition Fund Management's Axsome Therapeutics position peaked at $3.38M in Q1 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.